Spotlight Commentary: Importance of dose redefining in the process of drug repurposing
Open Access
- 5 November 2020
- journal article
- editorial
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 87 (4) , 1705-1707
Abstract
No abstract availableKeywords
This publication has 10 references indexed in Scilit:
- COVID-19: immunopathology and its implications for therapyNature Reviews Immunology, 2020
- Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitroCell Discovery, 2020
- Gabapentin and pregabalin to treat aggressivity in dementia: a systematic review and illustrative case reportBritish Journal of Clinical Pharmacology, 2018
- Preliminary evidence that vortioxetine may improve sleep quality in depressed patients with insomnia: a retrospective questionnaire analysisBritish Journal of Clinical Pharmacology, 2018
- The journey of metformin from glycaemic control to mTOR inhibition and the suppression of tumour growthBritish Journal of Clinical Pharmacology, 2018
- Additional evidence for a therapeutic effect of dextromethorphan/quinidine on bulbar motor function in patients with amyotrophic lateral sclerosis: A quantitative speech analysisBritish Journal of Clinical Pharmacology, 2018
- Inventing new therapies without reinventing the wheel: the power of drug repurposingBritish Journal of Pharmacology, 2018
- Use of Low-Dose Gabapentin for Aggressive Behavior in Vascular and Mixed Vascular/Alzheimer DementiaThe Journal of Neuropsychiatry and Clinical Neurosciences, 2013
- Mechanism mattersNature Medicine, 2010
- Sildenafil in the treatment of pulmonary hypertensionVascular Health and Risk Management, 2006